556 related articles for article (PubMed ID: 31604467)
1. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
3. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
[TBL] [Abstract][Full Text] [Related]
5. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
8. Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer.
Otsuka R; Iwasa S; Yanai T; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Hashimoto H; Sekiguchi M; Makino Y; Boku N; Yamaguchi M
Int J Clin Oncol; 2020 Apr; 25(4):595-601. PubMed ID: 31853798
[TBL] [Abstract][Full Text] [Related]
9. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
[TBL] [Abstract][Full Text] [Related]
11. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
[TBL] [Abstract][Full Text] [Related]
12. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Shimoyama R; Yasui H; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N; Todaka A; Tomita H; Sakamoto T; Tsushima T
Gastric Cancer; 2009; 12(4):206-11. PubMed ID: 20047125
[TBL] [Abstract][Full Text] [Related]
17. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
Kawamoto Y; Komatsu Y; Yuki S; Sawada K; Muranaka T; Harada K; Nakatsumi H; Fukushima H; Ishiguro A; Dazai M; Hatanaka K; Nakamura M; Iwanaga I; Uebayashi M; Sogabe S; Kobayashi Y; Miyagishima T; Ono K; Sakamoto N; Sakata Y
BMC Cancer; 2017 Dec; 17(1):837. PubMed ID: 29221445
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen.
Murad AM; Petroianu A; Guimaraes RC; Aragao BC; Cabral LO; Scalabrini-Neto AO
Am J Clin Oncol; 1999 Dec; 22(6):580-6. PubMed ID: 10597742
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
20. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).
Pachman DR; Qin R; Seisler D; Smith EM; Kaggal S; Novotny P; Ruddy KJ; Lafky JM; Ta LE; Beutler AS; Wagner-Johnston ND; Staff NP; Grothey A; Dougherty PM; Cavaletti G; Loprinzi CL
Support Care Cancer; 2016 Dec; 24(12):5059-5068. PubMed ID: 27534963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
